Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland

About this trial

The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

At least 18 years of age

For stage 0: Individuals without overweight/obesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD)

Individuals with overweight/obesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD

Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD

Disqualifiers

Individuals with CKM syndrome stage 4 according to the AHA

History of coronary artery disease, myocardial infarction, coronary artery intervention

History of atrial fibrillation

History of stroke

Trial population

Approximately 200-300 participants with cardiovascular-kidney-metabolic (CKM) syndrome per year at the Medical Outpatient Department of the University Hospital Basel

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Frequency of cardiovascular diseases

Out of available clinical data from the local electronic health record the frequency of cardiovascular diseases (e.g. stroke, myocardial infarction, coronary artery disease, peripheral arterial disease, hypertension, heart failure) will be assessed

Time frame
At baseline, 6, 12 months and annually up to 10 years
2

Frequency of kidney diseases

Out of available clinical data from the local electronic health record the frequency of kidney diseases (e.g. chronic kidney disease, kidney failure) will be assessed

Time frame
At baseline, 6, 12 months and annually up to 10 years
3

Frequency of liver diseases

Out of available clinical data from the local electronic health record the frequency of liver diseases (e.g. Metabolic Dysfunction-associated steatotic liver disease, MASLD) will be assessed

Time frame
At baseline, 6, 12 months and annually up to 10 years
4

Frequency of metabolic diseases

Out of available clinical data from the local electronic health record the frequency of metabolic diseases (e.g. dyslipidemia, pre-/diabetes) will be assessed

Time frame
At baseline, 6, 12 months and annually up to 10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: